Pfizer CEO: AI will help with medicine's next big breakthrough

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Bourla found collaboration with Kennedy very productive in many areas, including the HHS agreements announced at White House

  80% confidence

• AI can help with target identification to find sites of cancer cells that create resistance to medicines and cause metastasis

  80% confidence

• Trump is a disruptor who changes things people thought couldn't be changed

  80% confidence

• The big discrepancy between affluent countries and the US in drug pricing was provocative and not sustainable

  80% confidence

• Metsera's oral peptides are well-formulated and don't require taking on empty stomach

  80% confidence

• President Trump is more experienced in managing government in his second term and very determined

  80% confidence

• AI will have a profound impact on medicine, with current capabilities exceeding what most companies are utilizing

  80% confidence

• Pfizer has the right to win in the obesity space due to expertise in primary care, large-scale trials, manufacturing at scale, and top-ranked field force

  80% confidence

• Bobby Kennedy would not have been Bourla's choice for HHS secretary, but he tries to work constructively

  80% confidence

• AI can design medicines and molecules that fit targets much faster and better than traditional methods

  80% confidence

• The key challenge with AI is integrating it into business processes and operations, which creates anxiety and resistance

  80% confidence

• U.S. consumers pay for medicines as if they don't have insurance although they do, unlike hospital or MRI costs

  80% confidence

• Pfizer products from Metsera acquisition should hit market by 2028 if they move fast

  80% confidence

• Animal testing for safety can be replaced in silico with AI models that accurately predict molecule behavior in toxicology and pharmacodynamics

  80% confidence

• Bourla and Kennedy have very big disagreements on vaccines and some scientific FDA approaches

  80% confidence

• Pfizer committed to invest $70 billion in the US over the next 3-5 years

  80% confidence

• Vaccines will not go back to pre-Pasteur times long-term because vaccines have saved the world and are the most cost-effective medical intervention

  80% confidence

• Metsera has a monthly GLP-1 product and no one else is as advanced in monthly GLP-1

  80% confidence

• Pfizer plans to invest significantly to win in obesity space, following comprehensive and deep development plan

  80% confidence

• Many medicines are dependent on China but Pfizer has no dependency - doesn't export from China or import anything from China to the US

  80% confidence

• If a leader's defining characteristic is optimism, Bourla believes his is on the very high end of the spectrum

  80% confidence

• Pfizer has 11 manufacturing sites and 2 gigantic logistics centers (13 total) in the US, mostly in the South and Midwest

  80% confidence

• Pfizer's leading position will be in oncology in the near future, and will also play to be a leader in obesity

  80% confidence

• Pfizer's two lead obesity assets failed one after the other about a year ago

  80% confidence

• Consumer drug prices on average are double the prices Pfizer charges in the US

  80% confidence

• The acquisition's value depends on whether it works - if it works, it's worth the investment big time; if not, they overpaid

  80% confidence

• Bourla's optimism comes from his mother, a Holocaust survivor who emphasized that nothing is impossible

  80% confidence

• Pfizer's primary care field force has been ranked number one consecutively for the last 10 years in the US

  80% confidence

• Drug pricing changes should be implemented beginning of the year 2026

  80% confidence

• Pfizer will build manufacturing capacity for Metsera products in the US to provide US patients with US-produced anti-obesity drugs

  80% confidence

Data points we hold from this source

Cited in these Via News reports

• Pfizer Joins the Global Obesity Race: GLP-1 Market Entry Planned by 2028 Following Metsera Acquisition →